香苏和胃颗粒治疗非糜烂性胃食管反流病(肝胃郁热证):多中心随机双盲安慰剂对照试验
本研究为多中心、随机、双盲、安慰剂对照III期试验,纳入480例非糜烂性胃食管反流病(NERD)且肝胃郁热证患者,按3:1随机接受香苏和胃颗粒或安慰剂治疗8周。结果显示,试验组烧心和反酸的视觉模拟量表(VAS)评分应答有效率及中医证候积分改善均显著优于对照组,且安全性良好。结论提示该药在特定NERD人群中有效,但需进一步研究其广泛适用性及与标准质子泵抑制剂治疗的比较效果。
要点
- 香苏和胃颗粒可显著改善NERD肝胃郁热证患者的烧心、反酸症状及中医证候积分。
- 研究纳入幽门螺杆菌阴性、无pH-阻抗表型且焦虑抑郁评分低的特定人群。
- 疗效与安全性在8周治疗中得到验证,但外推至广泛NERD人群需谨慎。
核心结论
- 在幽门螺杆菌阴性、无pH-阻抗表型且焦虑抑郁评分低的NERD肝胃郁热证患者中,香苏和胃颗粒改善烧心、反酸及中医证候积分有效且安全。
- 对更广泛NERD人群的普适性及与标准质子泵抑制剂治疗的比较效果需进一步研究。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照III期试验,纳入480例18-65岁确诊NERD(GerdQ≥8;幽门螺杆菌阴性)且中医肝胃郁热证患者。
- 按3:1随机分配接受香苏和胃颗粒或安慰剂,每日三次,疗程8周。
- 主要结局为第8周基于烧心和反酸视觉模拟量表(VAS)评分的应答有效率。
主要发现
- 第8周烧心VAS评分应答有效率试验组76.39% vs 对照组21.01%(95% CI 55.38 (45.98, 62.94)%,p < 0.01)。
- 第8周反酸VAS评分应答有效率试验组79.72% vs 对照组23.53%(95% CI 56.39 (46.90, 64.12)%,p < 0.01)。
- 第8周中医证候积分应答有效率试验组69.23% vs 对照组30.13%(p < 0.01)。
关键数值与推荐
- NERD诊断标准:GerdQ≥8且幽门螺杆菌阴性。
- 中医证型:肝胃郁热证。
- 主要疗效指标:第8周烧心、反酸VAS评分应答有效率。
临床怎么用
- 对于幽门螺杆菌阴性、无pH-阻抗表型且焦虑抑郁评分低的NERD肝胃郁热证患者,可考虑使用香苏和胃颗粒改善烧心、反酸及中医证候。
- 使用前需明确中医辨证为肝胃郁热证,并排除幽门螺杆菌感染。
- 目前证据不支持将结果直接外推至所有NERD患者或替代标准质子泵抑制剂治疗。
局限性
- 研究人群限定于幽门螺杆菌阴性、无pH-阻抗表型且焦虑抑郁评分低的NERD患者,外推性受限。
- 未与标准质子泵抑制剂治疗进行头对头比较。
- 摘要未报告安慰剂组1例退出后是否纳入分析的具体处理细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Xiangsu Hewei Granules are an herbal preparation that has shown potential for controlling symptoms of nonerosive gastroesophageal reflux disease (NERD) in preliminary studies. However, high-quality randomized controlled evidence for its use in NERD remains lacking. AIM: To verify the efficacy and safety of Xiangsu Hewei Granules in treating NERD with liver stomach stagnation heat syndrome. MATERIALS AND METHODS: This randomized, double-blind, placebo-controlled, multicentre phase III trial included 480 patients (aged 18-65 years) with confirmed NERD (GerdQ≥8; negative H. pylori) and traditional Chinese medicine (TCM) liver stomach stagnation heat syndrome. Patients were randomized 3:1 to receive either Xiangsu Hewei Granules or placebo, thrice daily for 8 weeks. The primary outcomes were the effective rate of the response based on visual analog scale (VAS) scores for heartburn and acid regurgitation at week 8. The secondary outcomes included reductions in the TCM syndrome score, etc. RESULTS: 479 participants (mean age 48.5 years, SD10.2; 54.3% female) entered the full analysis set and safety set (360 tests group; 119 control group, 1 participant in the control group withdrawing before medication). At week 8, compared with the control group, the test group demonstrated significantly better effective rate of VAS score response for heartburn(76.39% vs 21.01%, 95% CI 55.38 (45.98, 62.94) %, p < 0.01),acid regurgitation (79.72% vs 23.53%, 95% CI56.39 (46.90, 64.12) %, p < 0.01), and TCM syndrome score (69.23% vs 30.13%, p < 0.01) at week 8. CONCLUSION: In this selected population of NERD patients with liver-stomach stagnation heat syndrome (e.g., negative H. pylori, no pH-impedance phenotype, and low anxiety/depression scores), Xiangsu Hewei Granules demonstrated efficacy and safety in improving heartburn, acid regurgitation, and TCM syndrome scores. However, generalizability to the broader NERD population and its comparative effectiveness against standard proton pump inhibitor therapy require further investigation.
引用
- Chen ZM, Li J, Huang Z, et al. Chinese herbal medicine Xiangsu Hewei Granules in treating non-erosive gastroesophageal reflux disease with liver stomach stagnation heat syndrome: A multicentre, randomized, double-blind, placebo-controlled trial. J Ethnopharmacol. 2026. PMID: 42372807. doi:10.1016/j.jep.2026.122141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。